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Abstract
Purpose The aim of this study was to compare disease-free
survival (DFS) and overall survival (OS) between clinically
node-positive breast cancer patients, treated with neoad-
juvant chemotherapy (NAC), with axillary pathologic
complete response (ypN0), residual axillary isolated tumor
cells or micrometastases (ypNitc/mi), and residual axillary
macrometastases (ypN1-3).
Methods All patients diagnosed with clinically node-pos-
itive primary invasive breast cancer treated with NAC and
subsequent axillary lymph node dissection between 2005
and 2008 were retrospectively analyzed. Data were
obtained from the Netherlands Cancer Registry. Patients
were stratified by final pathological axillary status: ypN0,
ypNitc/mi, or ypN1-3. The main outcome measures DFS
and OS were analyzed using Kaplan–Meier survival anal-
ysis. Uni- and multivariable cox regression analyses were
used to determine independent predictors for DFS and OS.
Results A total of 1347 patients were included. Pathologic
nodal status was ypN0 in 22.2%, ypNitc/mi in 3.8%, and
ypN1-3 in 74.0% of patients. Overall, 5-year DFS was
57.8% and mean OS was 7.4 years. DFS and OS were
comparable between ypN0 and ypNitc/mi (HR 1.38
(0.40–4.79, p = 0.613) and HR 0.92 (0.27–3.09,
p = 0.889), respectively), but significantly different
between ypN0 and ypN1-3 (HR 1.78 (1.06–3.00,
p = 0.031) and HR 1.70 (1.07–2.71, p = 0.026),
respectively).
Conclusions Clinically node-positive patients, treated with
NAC, with axillary nodal status ypN0 or ypNitc/mi carry
similar prognosis regarding DFS and OS. Axillary nodal
status ypN1-3 is associated with a less favorable prognosis.
Future studies should consider ypN0 and ypNitc/mi as one
entity.
Keywords Breast cancer  Axillary lymph node 
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Introduction
Over the past 20 years, a trend toward a less invasive
approach regarding the surgical management of the axilla
in breast cancer patients has been observed. Nowadays, a
sentinel lymph node biopsy (SLNB) has been widely
adopted for staging of early-stage clinically node-nega-
tive breast cancer [1]. In case of a sentinel lymph node
(SLN) containing isolated tumor cells (ITCs) or
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micrometastases, a completion of axillary lymph node
dissection (ALND) does not improve survival, nor does it
reduce regional recurrence. Consequently, ALND fol-
lowing SLNB has been abandoned in these patients [2–4].
The ACOSOG Z0011 trial demonstrated no significant
effect on prognosis when ALND is omitted in case of a
SLN containing a limited number of metastases, even
macrometastases, in patients treated with breast con-
serving therapy [3].
In clinically node-positive (cN?) patients, ALND is
regarded as standard surgical therapy. However, increased
utilization of neoadjuvant chemotherapy (NAC) results in
axillary pathologic complete response (pCR) in 30–40% of
patients [5]. Consequently, the value of ALND is topic of
debate. Various studies demonstrated that axillary pCR
after NAC is associated with improved prognosis [6–8].
Residual axillary disease has a less favorable prognosis, but
it is unknown whether different degrees of residual axillary
disease (i.e., ITCs, micrometastases, macrometastases) all
have similar prognosis.
Hence, the purpose of this study was to compare prog-
nosis of axillary pCR, residual ITCs, or micrometastases
and residual macrometastases in cN? patients treated with
NAC.
Methods
Data collection
In this study, all pathologically confirmed cN? patients
diagnosed with primary invasive breast cancer and treated
with NAC (with or without immunotherapy) followed by
ALND between 2005 and 2008 were included. Exclusion
criteria were synchronous breast cancer, primary surgical
treatment, neoadjuvant radiation therapy, neoadjuvant
endocrine therapy, unknown pathological nodal status, and
distant metastases diagnosed within 91 days after primary
breast cancer diagnosis. Patients who did not undergo
ALND were also excluded.
Data were obtained from the Netherlands Cancer Reg-
istry (NCR), which is managed by the Netherlands Com-
prehensive Cancer Organisation (NCCO). The PALGA
foundation (Pathologisch-Anatomisch Landelijk Geau-
tomatiseerd Archief), a nationwide network and registry of
histopathology and cytopathology diagnosis in the
Netherlands, regularly submits reports of all diagnosed
malignancies to the cancer registry. After notification,
trained data collection registrars from the NCR extracted
data from patients’ records. Data were collected on age,
tumor type, receptor status, surgical procedures, systemic
therapy, adjuvant radiation therapy, and pathology results,
including pathological TNM stage and tumor grade. During
a 5-year period after initial diagnosis, the first of the fol-
lowing breast cancer events was registered: any local,
regional, or contralateral recurrence or distant metastasis.
Date of death or date of emigration was derived from the
Municipal Personal Records Database (Basisregistratie
Personen, BRP) and files until December 31, 2014 were
analyzed.
Patients were stratified into three subgroups according to
final pathologic axillary nodal status after completion of
NAC and definitive surgery: pCR (ypN0), residual isolated
tumor cells or micrometastases (ypNitc/mi), and residual
macrometastases (ypN1-3).
Neoadjuvant chemotherapy (NAC) with/without
immunotherapy regimen
During the study period, the Dutch national guideline of
2005 was in use [9]. This guideline recommended
chemotherapy regimens consisting of five courses 5 Fluo-
rouracil, Epirubicin, Cyclophosphamide (FEC), or six
courses of Taxotere, Adriamycin, and Cyclophosphamide
(TAC). In case of Her2Neu receptor (Her2) amplification,
targeted therapy (trastuzumab) was recommended in
addition to chemotherapy.
Statistics
Statistical analyses were performed using Statistical
Package for the Social Sciences software (Version 22,
IBM, Armonk, New York, USA). General characteristics
between the three subgroups were compared using Chi
squared test for categorical data and One-way ANOVA for
continuous data, after confirmation of Levene’s test for
equality of variances. If Levene’s test demonstrated sig-
nificant differences among the population variances,
Kruskall–Wallis test was used.
DFS was defined as time from diagnosis to any local
(including carcinoma in situ), regional, or contralateral
recurrence, distant metastasis or mortality within 5 years
after the primary diagnosis. Events occurring 0–91 days
after diagnosis were considered synchronous to the original
tumor and were not counted as recurrence. OS was defined
as the time interval between date of diagnosis and date of
death, date of first event, date of last follow-up, or date of
emigration.
DFS and OS for the three subgroups were calculated
with Kaplan–Meier curves and compared with the log-rank
test. p values (two-sided)\0.05 were considered statisti-
cally significant. Relevant clinicopathological variables
associated with DFS and OS were examined using uni-
variable and, where applicable, multivariable Cox propor-
tional hazards regression, with Hazard Ratio (HR) and
corresponding 95% confidence intervals.
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Results
Between 2005 and 2008, 8176 patients were diagnosed
with cN? breast cancer in the Netherlands. Patients were
excluded for several reasons: 6553 patients underwent
primary surgery; 204 patients did not undergo ALND; 9
patients were treated with neoadjuvant radiotherapy; 61
patients were treated with neoadjuvant endocrine therapy;
and ypN status was unknown for 11 patients (Fig. 1). A
final total of 1347 patients were included for this study: 299
ypN0, 51 ypNitc/mi and 997 ypN1-3.
The incidence of pCR of the primary tumor was higher
in patients with ypN0 compared to ypNitc/mi and ypN1-3
patients (41.1 vs. 19.6 and 7.1%, respectively, p\ 0.001).
Furthermore, lobular carcinoma was observed more often
in patients with ypN1-3 than in ypN0 and ypNitc/mi
patients (9.4 vs. 5.4 and 3.9%, respectively, p = 0.039).
Adjuvant radiation therapy was applied more often in
ypN1-3 as compared to ypN0 and ypNitc/mi patients (92.1
vs. 80.9 and 80.4%, respectively, p\ 0.001, Table 1).
Disease-free survival
Five-year follow-up was available for 944 patients (70.1%;
n = 206 ypN0, n = 34 ypN0i?/ypN1mi, n = 704 ypN1-
3): Recurrence occurred in 377 patients (39.9%) and 22
patients died within 5 years (2.3%). This resulted in a DFS
event in 42.2% of the patients. DFS did not differ signifi-
cantly between ypN0 and ypNitc/mi (71.8 vs. 70.6%,
p = 0.978). When DFS was compared between ypN0 and
ypN1-3, a significant difference was found (71.8 vs. 53.4%;
p = 0.049) (Fig. 2a).
Multivariable Cox regression analyses demonstrated no
significant difference in DFS between ypN0 and ypNitc/mi
(HR 1.38 (0.40–4.79), p = 0.613), but a significant dif-
ference in DFS between ypN0 and ypN1-3 (HR 1.78
(1.06–3.00), p = 0.031) (Table 2).
Furthermore, higher ypT stage (ypT 1-2: HR 2.73
(1.39–5.39), p = 0.004 and ypT 3-4: HR 4.71 (2.35–9.43),
p\ 0.001) and higher tumor grade (HR 1.69 (1.19–2.40),
p = 0.004) were identified as independent predictors of
decreased DFS, whereas endocrine therapy was identified
as independent predictor of increased DFS (HR 0.55
(0.36–0.85), p = 0.007).
Overall survival
Mean OS was 7.4 years (range 0.4–10 years): 8.3 years for
ypN0, 8.2 years for ypNitc/mi, and 7.0 years for ypN1-3
(Fig. 2b). OS was comparable between ypN0 and ypNitc/
mi (p = 0.875). However, OS was significantly lower for
ypN1-3 as compared to ypN0 (p = 0.014).
Multivariable Cox regression analyses demonstrated no
significant difference in OS between ypN0 and ypNitc/mi
(HR: 0.92 (0.27–3.09), p = 0.889), but a significant dif-
ference in OS between ypN0 and ypN1-3 (HR 1.70
(1.07–2.71)), p = 0.026) (Table 3).
Other independent predictors of decreased OS were
higher ypT stage (ypT 1-2: HR 2.40 (1.32–4.36),
p = 0.004) and ypT 3-4: HR 4.38 (2.37–8.12), p\ 0.001)
and higher tumor grade (HR 1.72 (1.25–2.36), p = 0.001).
Furthermore, endocrine therapy (HR 0.49 (0.34–0.72),
p\ 0.001) was identified as an independent predictor of
increased OS.
Fig. 1 Flowchart of included
patients. cN? clinically node-
positive status, SLNB sentinel
lymph node biopsy, ALND
axillary lymph node dissection,
ypN0 axillary pathologic
complete response, ypNitc/mi
axillary residual isolated tumor
cells or micrometastases, ypN1-
3 axillary residual
macrometastases
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Discussion
This is the first study comparing prognosis of ypN0 with
ypNitc/mi and ypN1-3 in cN? breast cancer patients
treated with NAC. It is well known that axillary pCR is an
important prognostic factor [6–8]. Residual axillary disease
after completion of NAC is associated with a less favorable
prognosis. However, to our knowledge, this is the first
study that compares the long-term effect of different
degrees of residual disease on prognosis. Our study showed
that ypN0 and ypNitc/mi carry similar prognosis and that
ypN1-3 carries a significantly different and less favorable
prognosis in terms of DFS and OS.
Current guidelines still recommend to perform ALND in
cN? patients following NAC irrespective of axillary
response [10, 11]. However, cN? patients converting to
Table 1 General characteristics
ypN0 (n = 299) ypNitc/mi (n = 51) ypN1-3 (n = 997) p value
Mean age (years) (range) 48.9 (27–77) 48.2 (29–81) 50.4 (22–85) 0.053
Clinical T-stage (%)
cT0-is 1 (0.3) 0 5 (0.5) 0.826
cT1-2 138 (47.0) 26 (52.0) 458 (47.0) 0.780
cT3-4 153 (52.0) 24 (48.0) 509 (52.0) 0.853
cTx 7 1 25 –
Pathologic T-stage (%)
ypT0-is 123 (50.8) 10 (26.3) 71 (8.5) \0.001
ypT1-2 107 (44.2) 25 (65.8) 570 (68.5) \0.001
ypT3-4 12 (5.0) 3 (7.9) 191 (23.0) \0.001
Unknown 57 13 165 –
Tumor grade (%)
1–2 28 (31.5) 7 (50.0) 197 (43.9) \0.001
3 61 (68.5) 7 (50.0) 252 (56.1) 0.051
Unknown 210 37 548 –
Tumor type (%)
Ductal 227 (75.9) 41 (80.4) 746 (74.8) 0.739
Lobular 16 (5.4) 2 (3.9) 94 (9.4) 0.039
Othera 56 (18.7) 8 (15.7) 157 (15.8) 0.470
Subtype (%)
ER?PR? , Her2- 35 (12.8) 11 (22.5) 349 (37.3) \0.001
ER?PR-, Her2- 21 (7.7) 7 (14.3) 122 (13.0) 0.035
ER?Her2? 47 (17.1) 20 (40.8) 152 (16.3) \0.001
ER-Her2? 97 (35.4) 5 (10.2) 146 (15.6) \0.001
Triple negative 74 (27.0) 6 (12.2) 166 (17.8) 0.003
Unknown 25 2 62 –
Breast surgery (%)
Breast conserving therapy 62 (20.7) 12 (23.5) 181 (18.2) 0.421
Mastectomy 237 (79.3) 39 (76.5) 816 (81.8) 0.421
Unknown 0 0 1 –
Radiation therapy (%)
Yes 242 (80.9) 41 (80.4) 918 (92.1) \0.001
Endocrine therapy to ER? subtype (%)
Yes 95 (84.8) 35 (92.1) 600 (91.5) 0.080
Trastuzumab to Her2? subtype (%)
Yes 127 (92.0) 19 (76.0) 247 (89.2) 0.057
ypN0 axillary pathologic complete response, ypNitc/mi axillary residual isolated tumor cells or
micrometastases, ypN1-3 axillary residual macrometastases, cT-stage clinical tumor stage, pT-stage
pathologic tumor stage, ER estrogen, PR progesterone, Her2 human epidermal growth factor receptor 2
a Including adenocarcinoma not otherwise specified, mucinous carcinoma, and mixed carcinoma
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axillary pCR after completion of NAC remain a topic of
debate since they are not expected to benefit from ALND.
A non-invasive technique to accurately diagnose pCR is
currently unavailable. Various minimally invasive proce-
dures have been suggested for this purpose. The SLNB was
studied extensively and its reliability seems questionable
with a reported overall false negative rate (FNR) of 15.1%
and negative predictive values (NPV) of 86% or lower [5].
Other recently introduced minimally invasive techniques,
the MARI procedure (Marking the Axillary lymph node
with Radioactive Iodine seeds) and TAD (Targeted Axil-
lary Dissection), are promising with FNRs of 7 and 2%,
respectively. However, with only evidence available of
single center studies comprising small cohorts that support
these techniques it is not (yet) safe to implement them in
clinical practice [12, 13].
In our cohort, all patients underwent an ALND and thus
our results do not directly support a change in surgical
axillary treatment after the completion of NAC. Consid-
ering the comparable prognosis between ypN0 and
ypNitc/mi, our results do question whether ypNitc/mi may
mimic ypN0 more than residual axillary disease. Thus,
when minimally invasive procedures prove to predict the
status of the axilla accurately, the indications for omitting
ALND may not just be limited to ypN0. Therefore, cur-
rent research on reducing axillary management in
cN? patients should not focus only on ypN0 patients, but
also on patients with ypNitc/mi. In future, ALND may be
rendered as a procedure only to manage residual
macrometastases.
In clinically node-negative patients in adjuvant setting,
the SLNB with a relatively high FNR of about 8% is
permitted since axillary recurrences are rare and previous
studies have shown that not all axillary residual disease
eventually converts to clinically overt disease [2, 3, 14].
This is in part effectuated by adjuvant therapy (i.e., radi-
ation and/or systemic therapy) and by biological subtypes
influencing recurrence patterns. In cN? patients, however,
no studies have adequately evaluated prognostic impact of
omitting ALND in case of residual axillary disease. Despite
this, a trend toward replacing ALND by less invasive
axillary staging procedures that are known to miss poten-
tially therapy-resistant disease is already ongoing world-
wide. Therefore, it is of utmost importance to prospectively
collect data of these patients to detect potential influences
on prognosis.
Since prognosis seems comparable between post-ALND
ypN0 and ypNitc/mi in cN? patients treated with NAC,
imaging might play an important role in axillary staging
after NAC in the future. Since ITCs and micrometastases
are not detectable on high-resolution exams, such as MRI
or 18F-FDG PET/CT, imaging techniques were considered
inaccurate for nodal assessment after completion of NAC.
Yet, with our current observations in mind, dedicated
axillary imaging is re-entering the arena as a modality to
non-invasively identify residual macrometastases rather
than ‘any’ extent of residual disease (including ITCs and
micrometastases).
The strength of the current study is the large cohort of
patients that all underwent ALND after NAC. But our
ypN0 206 188 172 152 146 80
ypNitc/mi 34 32 28 27 25 15
ypN1-3 704 598 499 423 381 241
ypN0 299 263 236 43
ypNitc/mi 51 43 38 9
ypN1-3 997 795 612 109
a b
Fig. 2 Kaplan–Meier curves for disease-free (a) and overall survival
(b), including number at risk. ypN status pathologic nodal status after
neoadjuvant chemotherapy, ypN0 axillary pathologic complete
response, ypNitc/mi axillary residual isolated tumor cells or
micrometastases, ypN1-3 axillary residual macrometastases
Breast Cancer Res Treat (2017) 163:159–166 163
123
study also has several limitations. Subgroups ypN0 and
ypN1-3 comprised 299 and 997 patients, respectively,
where subgroup ypNitc/mi comprised only 51 patients. Our
ypNitc/mi subcohort was too small to explore the influence
of single versus multiple tumor-positive lymph nodes on
prognosis, and further studies are needed to explore this
concept. Yet, this subset of patients can be considered
unique since ypNitc/mi in cN? breast cancer is rare and a
previously reported study included only a few ypNitc/mi
patients [15].
Furthermore, our cohort was treated up to a decade ago.
In that time frame, different guidelines were effective, and
therefore results should be interpreted carefully regarding
current practice. For example, some Her2? patients did
not receive trastuzumab in our cohort (19.6%), since tras-
tuzumab was just introduced by that time.
Finally, our results are based on a retrospective study
design. Consequently, details on additional radiation ther-
apy could not be taken into account since radiation therapy
fields were not recorded for each patient. Therefore, its
influence on prognosis could not be explored in more
detail.
In conclusion, our study showed that prognosis of
cN? patients who receive NAC is affected by the degree
of axillary residual disease as measured in ALND speci-
mens. Prognosis of isolated tumor cells and micrometas-
tases was comparable to prognosis of ypN0 and more
favorable than prognosis of macrometastases in terms of
DFS and OS irrespective of tumor type. Ongoing and
future studies should therefore consider ypN0 and ypNitc/
mi as one entity. Future research must explore which
patients may safely receive a different, less invasive
Table 2 Uni- and multivariable
analyses of predictors of
disease-free survival at 5 years
Univariable analysis Multivariable analysis
HR (95% CI) p value HR (95% CI) p value
ypN0 Reference 0.964 Reference 0.613
ypNitc/mi 1.02 (0.52–1.99) \0.001 1.38 (0.40–4.79) 0.031
ypN1-3 1.89 (1.43–2.50) 1.78 (1.06–3.00)
Age (per year increment) 1.02 (1.01–1.02) 0.001 1.01 (0.99–1.02) 0.479
ypT-stage
T0 or Tis Reference Reference
T1-2 1.88 (1.31–2.70) 0.001 2.73 (1.39–5.39) 0.004
T3-4 3.74 (2.53–5.54) \0.001 4.71 (2.35–9.43) \0.001
Tumor type
Ductal Reference Reference
Lobular 0.78 (0.53–1.14) 0.193 1.11 (0.59–2.07) 0.751
Other 0.89 (0.69–1.15) 0.386 0.89 (0.58–1.37) 0.595
Tumor grade
3 versus 1–2 1.64 (1.22–2.20) 0.001 1.69 (1.19–2.40) 0.004
Subtypes
ER?PR?Her2-: yes versus noa 0.63 (0.50–0.80) \0.001
ER?PR-Her2-: yes versus noa 1.32 (0.99–1.75) 0.057
ER?Her2?: yes versus noa,b 0.63 (0.47–0.85) 0.002
ER-Her2?: yes versus nob 1.20 (0.95–1.53) 0.129
Triple negative: yes versus no 1.94 (1.46–2.32) \0.001 1.16 (0.69–1.93) 0.577
Trastuzumab
Yes versus no 0.81 (0.65–1.00) 0.052 0.76 (0.47–1.23) 0.263
Endocrine therapy
Yes versus no 0.57 (0.47–0.69) \0.001 0.55 (0.36–0.85) 0.007
Radiation therapy
Yes versus no 1.09 (0.78–1.52) 0.626 0.74 (0.45–1.23) 0.251
HR hazard ratio, ypN0 axillary pathologic complete response, ypNitc/mi axillary residual isolated tumor
cells or micrometastases, ypN1-3 axillary residual macrometastases, ypT-stage pathologic tumor stage
after neo-adjuvant chemotherapy, ER estrogen, PR progesterone, Her2 human epidermal growth factor
receptor 2
a Excluded from multivariable analysis due to collinearity with endocrine therapy
b Excluded from multivariable analysis due to collinearity with trastuzumab
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approach than the current standard of performing ALND
after completion of NAC in all patients that were
cN? prior to NAC.
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